Articles by Michael G. Parker - Pharmaceutical Executive

ADVERTISEMENT

Articles by Michael G. Parker

Building Blockbusters

The most lucrative new drugs are often less glamorous than first-in-class NMEs. And they are much less risky.
Sep 1, 2005

Companies face a serious pipeline gap, partly because they focus too narrowly on scientific breakthroughs. Stakeholders also value convenient compounds with reduced side effects and fewer doses.

ADVERTISEMENT

Click here